Please login to the form below

Cornerstone Therapeutics

This page shows the latest Cornerstone Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Chiesi hits the acquisition trail again

Chiesi hits the acquisition trail again. Will buy US speciality pharma company Cornerstone. ... Italy's Chiesi has signed its second acquisition deal in as many months, agreeing a $9.50-a-share deal for US speciality pharma company Cornerstone

Latest news

Cornerstone slumps as FDA panel votes down lead pipeline drug

US pharma company Cornerstone Therapeutics suffered a setback after an FDA advisory committee voted against approval of lixivaptan, the firm's drug candidate for hyponatremia or low sodium levels in the ... It was originally developed by Wyeth and
Pharma deals for May 2012

This can effectively kill a deal and potentially the product. Another example of a product acquisition is InterMune's sale of its approved product, Actimmune (interferon gamma-1b), to Vidara Therapeutics ... NCEs for respiratory disease. 212. EKR
Biologics buoyant

Three of the deals, with Amplimmune, FivePrime Therapeutics and Genmab, focus on biologics. ... 84+. Cornerstone Therapeutics/Targacept . Alpha-7 and other nicotinic receptor targeting compounds. Preclinical .

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

Deal Watch table for September 2013

Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... Cornerstone Therapeutics, respectively.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Medical Writer: Great salary and bebefits

Senior Account Manager – Med Comms – Kent: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Account Manager – Med Comms – London: Salary TBC

Senior Account Manager / Account Director: Great salary and bebefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Scientific Director: Great salary and bebefits

Senior Medical Writer: Great salary and benefits

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior Programme Executive: Salary TBC

Senior Account Manager or AD - Medical Communications: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Subscribe to our email news alerts

PMHub

Add my company

EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Pharma’s isolated islands of innovation: With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit: What does it mean for the life science sector?...
The Holy Grail of HCP Access: This is the data you need to gain access....